Sleep disturbance in adults with untreated primary brain tumors: prevalence and impact on quality of life.

PURPOSE

To investigate the frequency of sleep disturbance and its effects on quality of life in adults with untreated primary brain tumors.

METHODS

This cross-sectional study recruited 68 and 35 patients with newly diagnosed benign and malignant brain tumors, respectively. All participants completed the Chinese versions of the Athens Insomnia Scale, Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Hospital Anxiety and Depression Scale, Brief Fatigue Inventory, and EORTC-QLQ-BN20 for quality-of-life assessment. An actigraph was used to measure sleep parameters [e.g., dichotomy index ( < )], for at least 3 consecutive days in untreated status.

RESULTS

The majority of the patients with benign and malignant tumors had meningioma (57.4%) and glioblastoma (40%), respectively. The prevalence of insomnia, poor sleep quality, and excessive daytime sleepiness was 59.2%, 77.7%, and 4.9%, respectively. The prevalence rates of sleep disturbances were not affected by tumor locations (suprasellar vs. non-suprasellar tumors) and tumor types (benign vs. malignant tumors). Only 36 participants completed actigraphy assessments ( <  = 95.4) due to having a tight schedule, actigraph malfunction, or not having the habit of wearing a wristwatch; 61% of them experienced circadian rhythm disruption ( <  ≤ 97.5). Insomnia was the only sleep parameter that significantly affected quality of life after controlling for potential confounders ( = 0.54,  = 0.03, adjusted  = 0.60).

CONCLUSION

More than 60% of the patients with primary malignant and benign brain tumors experienced insomnia, poor sleep quality, and circadian rhythm disruption. Insomnia was independently correlated with quality of life in untreated status. Health-care providers can apply these findings to design effective interventions targeting sleep disturbance to improve quality of life in this population.

SUPPLEMENTARY INFORMATION

The online version contains supplementary material available at 10.1007/s41105-022-00436-y.